Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johannes Lutz

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Schmerz (Berlin, Germany)|March 22, 2024
[Interdisciplinary multimodal pain therapy between "gold standard" and "terra incognita"]Rainer Sabatowski, Johannes Lutz
Journal of Immunology (Baltimore, Md. : 1950)|November 4, 2006
VH replacement rescues progenitor B cells with two nonproductive VDJ allelesJohannes Lutz, Werner Müller, Hans-Martin Jäck
Plos One|November 25, 2015
Effectiveness of a Multimodal Therapy for Patients with Chronic Low Back Pain Regarding Pre-Admission Healthcare UtilizationConstanze Borys, Johannes Lutz, Bernhard Strauss, et al.
International Immunology|January 22, 2004
Germinal center checkpoints in B cell tolerance in 3H9 transgenic miceElahna Paul, Johannes Lutz, Jan Erikson, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 20, 2017
mRNA Cancer VaccinesKatja Fiedler, Sandra Lazzaro, Johannes Lutz, et al.
Methods in Molecular Biology (Clifton, N.J.)|December 18, 2016
RNActive® Technology: Generation and Testing of Stable and Immunogenic mRNA VaccinesSusanne Rauch, Johannes Lutz, Aleksandra Kowalczyk, et al.
European Journal of Immunology|November 18, 2006
Genomic suppression of murine B29/Ig-beta promoter-driven transgenesChristian Vettermann, Johannes Lutz, Manuel Selg, et al.
Assessment|December 14, 2011
Construct validity of the Anxiety Sensitivity Index-3 in clinical samplesChristoph J Kemper, Johannes Lutz, Tobias Bähr, et al.
Scientia Pharmaceutica|October 10, 2013
Compounds from gum ammoniacum with acetylcholinesterase inhibitory activityHamid-Reza Adhami, Johannes Lutz, Hanspeter Kählig, et al.
Cancer Immunology, Immunotherapy : CII|November 2, 2022
Local immunotherapy with the RNA-based immune stimulator CV8102 induces substantial anti-tumor responses and enhances checkpoint inhibitor activityJohannes Lutz, Michael Meister, Mohamed Habbeddine, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Schmerz (Berlin, Germany)|March 22, 2024
[Interdisciplinary multimodal pain therapy between "gold standard" and "terra incognita"]Rainer Sabatowski, Johannes Lutz
Journal of Immunology (Baltimore, Md. : 1950)|November 4, 2006
VH replacement rescues progenitor B cells with two nonproductive VDJ allelesJohannes Lutz, Werner Müller, Hans-Martin Jäck
Plos One|November 25, 2015
Effectiveness of a Multimodal Therapy for Patients with Chronic Low Back Pain Regarding Pre-Admission Healthcare UtilizationConstanze Borys, Johannes Lutz, Bernhard Strauss, et al.
International Immunology|January 22, 2004
Germinal center checkpoints in B cell tolerance in 3H9 transgenic miceElahna Paul, Johannes Lutz, Jan Erikson, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 20, 2017
mRNA Cancer VaccinesKatja Fiedler, Sandra Lazzaro, Johannes Lutz, et al.
Methods in Molecular Biology (Clifton, N.J.)|December 18, 2016
RNActive® Technology: Generation and Testing of Stable and Immunogenic mRNA VaccinesSusanne Rauch, Johannes Lutz, Aleksandra Kowalczyk, et al.
European Journal of Immunology|November 18, 2006
Genomic suppression of murine B29/Ig-beta promoter-driven transgenesChristian Vettermann, Johannes Lutz, Manuel Selg, et al.
Assessment|December 14, 2011
Construct validity of the Anxiety Sensitivity Index-3 in clinical samplesChristoph J Kemper, Johannes Lutz, Tobias Bähr, et al.
Scientia Pharmaceutica|October 10, 2013
Compounds from gum ammoniacum with acetylcholinesterase inhibitory activityHamid-Reza Adhami, Johannes Lutz, Hanspeter Kählig, et al.
Cancer Immunology, Immunotherapy : CII|November 2, 2022
Local immunotherapy with the RNA-based immune stimulator CV8102 induces substantial anti-tumor responses and enhances checkpoint inhibitor activityJohannes Lutz, Michael Meister, Mohamed Habbeddine, et al.
Pageof 3